Biologics market

Biologics Market, By Product (Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, and Others), By Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Request Free Sample

May 2023
CMI2663
210 Pages
Excel & Pdf
Pharmaceutical

Summary

Global biologics market is estimated to be valued at US$ 401.96 Billion in 2023, exhibiting a CAGR of 9.3% during the forecast period (2023-2030). Global biologics market is expected to witness growth, owing to rising burden of chronic diseases and increasing demand for biologics across the globe. Moreover, rising demand and higher acceptability for innovative therapies and increasing clinical trials is expected to drive the market growth.

Analysts’ Views on Global Biologics Market:

Global biologics market growth is driven by increasing approval and laws from regulatory authorities. Biologics are used to treat the cancer. For instance, on March 07, 2023, CBER (Center for Biologics Evaluation and Research, the center within U.S Food And Drug Administration FDA that regulates biological products for human use, is approved under the federal laws including the Public Health Service Act and the Federal Food, and Drug and Cosmetic Act.

Figure 1. Global Biologics Market Share (%), By Product, 2023

Global Biologics Market– Drivers

Increasing Demand for Biologics products is associate the growth of Biologics Market

Biologics are used to treat cancer such as breast, lung, bladder, prostate, colorectum, and skin cancer. Thus, increase in prevalence of various cancer is likely drive the demand for biologics products and thereby drive the growth of market. For instance, according to World Health Organization, in 2020 estimated 10 million death occurred due to cancer globally

High Prevalence of Chronic Diseases

Rising burden of chronic diseases across the world is expected to drive the market growth. For instance, in September 2022, according to the World Health Organization (WHO), 41 million people die due to non-communicable diseases (NCD) every year, equivalent to 74% of all deaths worldwide. Every year, around 17 million people die from a NCD before age 70, and 86% of these premature deaths occur in globally.

Global Biologics Market- Regional Analysis

Among region, North America is expected to gain highest share in the market during the forecast period, owing to increasing prevalence of chronic, infectious, and autoimmune diseases. Biologics are used to treat a variety of conditions such as cancer, and thus, increasing burden of cancer boosts demand for of biologics. According to the American Cancer Society, in January 2022, 1.9 million new cancer cases were diagnosed in the U.S.

Figure 2. Global Biologics Market Share (%), By Region, 2023

Global Biologics Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

Factors that could hinder the growth of the biologics market in the future include high stringency and low turnover for clinical trials, stringent regulations related to bio similar approvals, prolonged production and approval time, and nomenclature challenges. Lockdowns and restrictions led to requirement for electronic data transfer and claim administration.

In particular, the now two-year-old pandemic has played a key role in changing the healthcare landscape, preventing many patients from managing their chronic diseases and increasing the risk of more serious illnesses for many underlying health conditions.

Global Biologics Management Market- Segmentation

Global biologics market report is segmented into product, application, and region

Based on Product, the market is segmented into monoclonal antibodies, vaccines, recombinant hormones/proteins, cellular-based biologics, gene-based biologics, and other. Out of which, monoclonal antibodies segment is expected to dominate the global biologics market over the forecast period, owing to increasing a burden of autoimmune diseases. Monoclonal antibodies are used to diagnose and treat autoimmune diseases and cancer.

Vaccines Segment is also expected to witness growth in the near future, owing to rising demand for safe and effective vaccines. Vaccine is a biological preparation that provides active acquired immunity to a particular infectious disease.

Based on Application, the market is segmented into cancer, infectious diseases, autoimmune diseases, and other. Out of which, cancer segment is expected to dominate the market over the forecast period, owing to increasing burden of cancer worldwide. Biologics are used to treat different types of cancer.

Based on Region, the market is segmented into North America, Latin America, Europe, Asia pacific, Middle East, and Africa. North America dominated the market over the forecast period. Market players operating in the region are focused on various strategies such as agreement, and this is expected to drive the market growth in this region.

Biologics Market Report Coverage

Report Coverage	Details
Base Year:	2022	Market Size in 2023:	US$ 401.96 Bn
Historical Data for:	2017 to 2021	Forecast Period:	2023 to 2030
Forecast Period 2023 to 2030 CAGR:	9.3%	2030 Value Projection:	US$ 749.46 Bn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product: Monoclonal Antibodies, Vaccines, Recombinant Hormones/Proteins, Cellular-based Biologics, Gene-based Biologics, Others By Application: Cancer, Infectious Diseases, Autoimmune Diseases, Others
Companies covered:	Novartis AG., AstraZeneca PLC., Bayer AG., Sanofi SA., Pfizer Inc., Merck & Co., Johnson and Johnson, GlaxoSmithKline PLC., Amgen Inc., AbbVie Inc., F. Hoffmann-La Roche AG., Eli Lilly and Company., and AGC Biologics.
Growth Drivers:	Increasing demand for biologics High prevalence of chronic diseases
Restraints & Challenges:	High capital investment

Global Biologics Market- Cross Sectional Analysis

Cancer segment is expected to witness growth in Europe and Asia Pacific, owing to rising burden of chronic diseases such cancer, and increasing research and development in these regions. For instance, August 2020, according to data based on current trends from the cancer report by Indian Council of Medical Research (ICMR), cancer cases in India will be increased by 12% and 1.5 million people will suffer from the non-communicable disease (NCD) by 2025, as compared to 1.39 million in 2020.

Global Biologics Market - Key Trends

Technological advancements is the recent trend

Artificial Intelligence (AI), Machine Learning (ML), and cloud-based and other software-assisted platforms for treatment are some of the technologies that are paving the path for the development of new products, opening new horizons for the growth in the market. Furthermore, the adoption of technology opens lots of opportunities for market players and emerging players in the market. This trend is expected to continue over the forecast period, driving the market growth.

Global Biologics Market- Key Developments

In April 2022, GSK, British multinational pharmaceutical and biotechnology company and SK bioscience, submitted a biologics license application for SKYCovione, a recombinant protein-based COVID-19 vaccine candidate, to the Korean Ministry of Food and Drug Safety (KMFDS)

In October 2021, Amgen, American multinational biopharmaceutical company acquired Teneobio, a clinical-stage biotechnology company developing a new class of biologics and human heavy-chain antibodies, for US$ 900 million, along with US$ 1.60 billion.

Global Biologics Market- Restraint

High Capital Investment

Manufacturing of biologics required the high capital investment thus it is expected to hamper the market growth. In September 2022, CuraTeQ Biologics, Biopharmaceutical Company planned to invest U$$ 0.30 on capacity expansion of biologics manufacturing facilities.

Global Biologics Market- Key Players

Major players operating in the global biologics market include Novartis AG., AstraZeneca PLC., Bayer AG., Sanofi SA., Pfizer Inc., Merck & Co., Johnson and Johnson, GlaxoSmithKline PLC., Amgen Inc., AbbVie Inc., F. Hoffmann-La Roche AG., Eli Lilly and Company, and AGC Biologics.

*Definition: Biologics market comprise companies manufacturing biological products that are derived from genetically modified proteins and human genes. Biologics products include a wide range of recombinant therapeutic proteins, gene therapy tissues, somatic cells, vaccines, and allergenic.

Table of Content

Table of Contents

*Browse 42 market data tables and 35 figures on “Global Biologics Market”- Global Forecast to 2030

Segmentation

Detailed Segmentation:

- Frequently Asked Questions -

What is the global biologics market size?

The global biologics market size was valued at US$ 401.96 in 2023 and is expected to reach US$ 749.46 Bn by 2030.

What are the major factors driving the Market growth?

Increasing demand of biologics product are expected to drive the market growth.

What are the key factors hampering the growth of the Market?

The major factor that can hamper growth of the market include high capital investment in research and development of biologics.

Which are the major players operating in the Market?

Major players operating in the include Novartis AG., AstraZeneca PLC., Bayer AG., Sanofi SA., Pfizer Inc., Merck & Co., Johnson and Johnson, GlaxoSmithKline PLC., Amgen Inc., AbbVie Inc., F. Hoffmann-La Roche AG., Eli Lilly and Company, and AGC Biologics

What will be the CAGR of market?

The market growing at a CAGR of 9.3% during the forecast period.